Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intensive therapy in multiple myeloma.

J L Harousseau1

  • 1Service d'Hématologie, Hôtel-Dieu, CHU, Nantes, France.

Pathologie-Biologie
|April 8, 1999
PubMed
Summary
This summary is machine-generated.

High-dose therapy (HDT) followed by autologous bone marrow transplantation significantly improves outcomes for newly diagnosed multiple myeloma patients under 65. HDT demonstrates superiority over conventional chemotherapy in response rates, event-free survival, and overall survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.

Cancer treatment reviews·2016
Same author

Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Bone marrow transplantation·2015
Same journal

Pathologie-biologie·2020
Same journal

Antibacterial and antibiofilm activities of Laurus nobilis L. essential oil against Staphylococcus aureus strains associated with oral infections.

Pathologie-biologie·2015
Same journal

[Not Available].

Pathologie-biologie·2015
Same journal

Oxidative damage and histopathological changes in lung of rat chronically exposed to nicotine alone or associated to ethanol.

Pathologie-biologie·2015
Same journal

Biological diagnosis of diabetes mellitus.

Pathologie-biologie·2015
Same journal

Association of CagPAI integrity with severeness of Helicobacter pylori infection in patients with gastritis.

Pathologie-biologie·2015
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • High-dose therapy (HDT) has gained prominence in multiple myeloma treatment over the last decade.
  • Conventional chemotherapy (CC) has been the standard treatment for multiple myeloma.

Purpose of the Study:

  • To compare the efficacy of HDT followed by autologous bone marrow transplantation versus CC in newly diagnosed multiple myeloma patients under 65.
  • To evaluate response rate, event-free survival, and survival in patients receiving HDT versus CC.

Main Methods:

  • The Intergroupe Français du Myelome conducted the first randomized trial comparing HDT with CC.
  • The study population included patients under 65 years of age with newly diagnosed multiple myeloma.

Main Results:

Related Experiment Videos

  • HDT demonstrated superior response rates compared to CC.
  • Patients receiving HDT showed improved event-free survival.
  • Overall survival was significantly better in the HDT group.

Conclusions:

  • HDT followed by autologous bone marrow transplantation is a superior treatment strategy for multiple myeloma patients under 65 compared to conventional chemotherapy.
  • Further research is needed to address issues such as HDT in older patients, conditioning regimens, stem cell sources, tandem transplants, and maintenance therapy.
  • Allogeneic bone marrow transplantation's role in younger patients remains uncertain due to high toxicity.